Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine

Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine
复制标题

DOI:
10.1086/516781
复制
发表时间:
2007-06-01
影响因子:
11.8
通讯作者:
Griffin, Marie R.
Griffin, Marie R.
中科院分区:
医学1区
文献类型:
--
作者:
Halasa, Natasha B.;Shankar, Sadhna M.;Griffin, Marie R.

文献摘要

被引文献

相似文献

背景我们试图确定在引入肺炎球菌结合疫苗(PCV)之前和之后,镰状细胞病(SCD)患者中侵袭性肺炎球菌病(IPD)的发病率。使用SCD特定的国际疾病分类第九版临床修改代码识别1995年1月至2004年12月期间参加田纳西州医疗补助的SCD患者。基于人群的监测数据用于识别IPD患者,并与田纳西州医疗补助数据库中的SCD患者相关联,以确定IPD的发病率。收集所有IPD患者的临床资料,并对所有可用的肺炎球菌分离株进行抗生素敏感性试验和血清分型。我们确定了2026名SCD患者,随访13,687人年。在研究期间,37名SCD患者发展为IPD,其中21名患者年龄< 5岁。PCV前(1995-1999年)与PCV后(2001-2004年)相比,2岁以下儿童的IPD发生率下降了90.8%(从3630例/10万人-年降至335例/10万人-年),P
Background. We sought to determine the incidence of invasive pneumococcal disease (IPD) among individuals with sickle cell disease (SCD) before and after the introduction of the pneumococcal conjugate vaccine (PCV).Methods. Individuals with SCD who were enrolled in Tennessee Medicaid from January 1995 through December 2004 were identified using SCD-specific International Classification of Diseases, Ninth Revision, Clinical Modification codes. Population-based surveillance data were used to identify individuals with IPD and were linked to patients with SCD in the Tennessee Medicaid database to determine incidence rates of IPD. Clinical data were collected on all subjects with IPD, and antibiotic susceptibility testing and serotyping were performed on all available pneumococcal isolates.Results. We identified 2026 individuals with SCD, who constituted 13,687 person-years of follow-up. During the study period, 37 individuals with SCD developed IPD, and 21 of these patients were aged < 5 years. In a comparison of the pre-PCV period (1995-1999) with the post-PCV period (2001-2004), the rate of IPD decreased by 90.8% in children aged < 2 years (from 3630 to 335 cases per 100,000 person-years;) and by 93.4% in P